Cardio-metabolic
Antihypertensives, statins, oral antidiabetics and fixed-dose combinations intended for long-term daily therapy.
- Telmisartan
- Metformin FDC
- Rosuvastatin
- Dapagliflozin
Established 2007 · WHO-GMP certified
Medicine that reaches the last mile.
Affordable, quality-assured formulations manufactured to WHO-GMP standards and supplied to 4,200 pharmacies, hospitals and government health programmes.
6
Therapy areas in focus
240+
Formulations in the portfolio
18
Countries supplied
2
Manufacturing facilities
640
People across plants & field
Who we are
A generics manufacturer that treats quality as the product.
Medicare Pharma makes finished-dose generics for chronic and acute care. We began in 2007 with a single oral-solids line and now operate two facilities, an analytical development laboratory, and a distribution network reaching 18 countries.
Our work is unglamorous by design. A tablet has to dissolve the same way in month one and month thirty-six, in Bengaluru and in Kampala. That means validated processes, retained samples for every batch, stability chambers held at 25 °C/60% RH and 40 °C/75% RH, and documentation that survives an audit without anyone scrambling.
Therapeutic areas
Where our portfolio is concentrated
Six areas account for roughly 85% of dispatched volume. Each is supported by its own formulation team and dedicated stability programme.
Anti-infectives
Broad-spectrum antibiotics, antifungals and antimalarials, including dispersible paediatric presentations.
- Amoxicillin–Clav
- Azithromycin
- Cefixime DT
- Fluconazole
Respiratory
Bronchodilators, leukotriene antagonists, antihistamines and mucolytic syrups for seasonal and chronic use.
- Montelukast
- Levocetirizine
- Ambroxol syrup
- Doxofylline
Gastro-intestinal
Proton pump inhibitors, prokinetics, enzyme preparations and ORS presentations for hospital and retail channels.
- Pantoprazole
- Rabeprazole–DSR
- Ondansetron
- ORS-L
Women’s health & nutrition
Haematinics, calcium and vitamin D combinations, prenatal supplements and therapeutic nutraceuticals.
- Ferrous ascorbate
- Calcium–D3
- Methylcobalamin
- Protein sachets
Dermatology & topicals
Creams, gels and ointments produced on a dedicated topicals line with segregated air handling.
- Clobetasol
- Ketoconazole
- Mupirocin
- Silver sulfadiazine
Research & development
Fourteen molecules moving through development
Development runs in defined stages. The bars show how far the current cohort of programmes has progressed through each one.
Stage 01
Product selection
- Patent and exclusivity check
- API sourcing and DMF review
- Market and price modelling
Stage 02
Formulation development
- Prototype trials at 1/10 scale
- Comparative dissolution profiling
- Excipient compatibility studies
Stage 03
Analytical & stability
- Method development and validation
- Accelerated 40 °C / 75% RH
- Long-term 25 °C / 60% RH
Stage 04
Bioequivalence
- Pilot study in fasted subjects
- Pivotal study at a partner CRO
- Statistical review of Cmax and AUC
Stage 05
Filing & scale-up
- CTD dossier compilation
- Exhibit batches at full scale
- Regulatory queries and approval
Global presence
Eighteen countries, four export regions
Exports move through registered local partners who hold the marketing authorisation in their own market. We handle dossier support, artwork in local languages and shipment documentation.
India — domestic
Retail, hospital and institutional supply through 4,200 pharmacies and 38 stockists.
Primary marketEast & West Africa
Kenya, Uganda, Tanzania, Nigeria, Ghana — anti-infectives and haematinics led.
5 countriesSouth-East Asia
Myanmar, Cambodia, Vietnam, Philippines — oral solids and topicals.
4 countriesMiddle East
UAE, Oman, Yemen, Iraq — registration under review in two further markets.
4 countriesCIS & neighbours
Uzbekistan, Kyrgyzstan, Nepal, Sri Lanka — supplied against annual tenders.
4 countriesNewsroom
Latest updates
21 Aug 2026Unit 2 topicals line clears WHO-GMP re-inspection with no critical observationsQuality
04 Aug 2026Dapagliflozin–Metformin fixed-dose combination completes pivotal bioequivalence studyPipeline
17 Jul 2026Rate contract awarded for paediatric dispersible anti-infectives in two state health programmesBusiness
02 Jun 2026Sachet and powder capacity expanded to 42 million units with a second form-fill-seal machineOperations
28 Apr 2026Registration dossiers filed in two additional Middle East marketsRegulatory